By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Medivation, Inc. 

525 Market Street
36th Floor
San Francisco  California  94105  U.S.A.
Phone: 415-543-3470 Fax: 415-543-3411


Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. The Company's current clinical development program includes a pivotal and confirmatory Phase 3 trial of Dimebon in Alzheimer's disease and a Phase 1-2 clinical trial of MDV3100 in patients with castration-resistant (also known as hormone-refractory) prostate cancer. Medivation recently announced that it plans to continue further development of Dimebon in patients with mild-to-moderate Huntington's disease based on the positive results seen in its Phase 2 trial.

For more information, please visit us at

Key Statistics

Ownership: Public

Web Site: Medivation
Employees: 18
Symbol: MDVN



Company News
Glass Lewis Recommends Medivation (MDVN)’s Stockholders Support The Company’s Current Board 6/24/2016 8:31:50 AM
Medivation (MDVN) Sets the Record Straight on Sanofi (SNY)’s Misleading Claims 6/24/2016 6:40:59 AM
Sanofi (SNY) Could Use the Same Tactics on Medivation (MDVN) that Were Instrumental in Acquiring Genzyme in 2011 6/23/2016 6:30:03 AM
If Spurned By Medivation (MDVN), Sanofi (SNY) May Turn to BioMarin (BMRN) for a Little Love 6/17/2016 7:03:01 AM
Medivation (MDVN) Files Definitive Consent Revocation Statement And Mails Letter To Stockholders 6/13/2016 8:21:58 AM
Sanofi (SNY) Wants to Oust Medivation (MDVN) Board by August 1 6/8/2016 6:09:47 AM
Former Medivation (MDVN) CMO Takes Helm at Roivant Sciences-Takeda (TKPYY)'s Newly Launched Company Myovant Sciences 6/6/2016 5:57:07 AM
Astellas (ALPMY) And Medivation (MDVN) Initiate Phase III Trial Of Enzalutamide In Patients With Triple-Negative Breast Cancer 6/2/2016 6:29:59 AM
Why Sanofi (SNY) is So Infatuated With the Bay Area’s Medivation (MDVN) 6/2/2016 6:24:33 AM
Medivation (MDVN) Files Preliminary Consent Revocation Statement 5/27/2016 8:12:15 AM